Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin in ambulatory COVID-19
NCT04381962Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azithromycin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Oxford. Primary endpoint: Proportion progressing to respiratory failure or death at 28 days. Started Jun 2020; status: completed.
02
Drugs
azithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04381962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381962.